Abstract
Drug-eluting stents (DES) present a slightly higher incidence of stent thrombosis compared to bare metal stents and some cases of DES thrombosis are described in the literature. Therefore, there is consensus in recommending treatment with clopidogrel for at least 6 months in addition to life-long aspirin administration. We describe a case of very late paclitaxel-eluting stent thrombosis despite 21 months of clopidogrel treatment, which occurred just 2 weeks after its withdrawal, causing an acute coronary syndrome that was promptly resolved with an urgent invasive strategy. In our experience, paclitaxel-eluting stent thrombosis can occur several months after stent implantation despite prolonged clopidogrel treatment.
MeSH terms
-
Acute Disease
-
Angioplasty, Balloon, Coronary / adverse effects*
-
Angioplasty, Balloon, Coronary / instrumentation
-
Cardiovascular Agents / administration & dosage*
-
Clopidogrel
-
Coronary Angiography
-
Coronary Thrombosis / complications
-
Coronary Thrombosis / diagnostic imaging
-
Coronary Thrombosis / etiology*
-
Coronary Thrombosis / prevention & control
-
Humans
-
Male
-
Middle Aged
-
Myocardial Ischemia / diagnostic imaging
-
Myocardial Ischemia / etiology*
-
Paclitaxel / administration & dosage*
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Practice Guidelines as Topic
-
Prosthesis Design
-
Stents*
-
Syndrome
-
Ticlopidine / analogs & derivatives*
-
Ticlopidine / therapeutic use
-
Time Factors
-
Treatment Outcome
Substances
-
Cardiovascular Agents
-
Platelet Aggregation Inhibitors
-
Clopidogrel
-
Ticlopidine
-
Paclitaxel